Leqembi (lecanemab) is an intravenous infusion therapy approved for the treatment of early Alzheimer's disease. It is specifically indicated for patients who meet certain criteria related to the stage of their disease and the presence of specific biomarkers.
Leqembi is primarily indicated for patients with early-stage Alzheimer's disease, particularly those with mild cognitive impairment (MCI) or mild dementia.
Patients should have confirmed amyloid-beta pathology, typically demonstrated through PET imaging or cerebrospinal fluid (CSF) analysis. This is crucial for determining eligibility.
While there is no strict age limit, most clinical trials have focused on older adults, generally over the age of 50, who exhibit early signs of cognitive decline.
Ideal candidates are those in the early stages of Alzheimer's, where they can still participate in daily activities and have a support system in place.
Patients should have a manageable health profile, without significant comorbidities that could complicate treatment or increase the risk of adverse effects.
Candidates should be able to understand the treatment's potential benefits and risks, ensuring they can give informed consent.
Importance of weighing the potential benefits of slowing cognitive decline against the risks of side effects, such as infusion-related reactions or amyloid-related imaging abnormalities (ARIA).
Leqembi is a monoclonal antibody designed to target amyloid beta plaques in the brain, which are associated with Alzheimer’s disease. Here’s how it works:
Mechanism of Action of Leqembi
Our team is always here to help. Send us a message and we'll get back to you shortly.